Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 93.17 EUR 2.53% Market Closed
Market Cap: 116.8B EUR
Have any thoughts about
Sanofi SA?
Write Note

Operating Margin
Sanofi SA

22.8%
Current
22%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
22.8%
=
Operating Profit
14B
/
Revenue
61.6B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Sanofi SA
PAR:SAN
116.6B EUR
23%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
710.5B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
373.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
CH
Roche Holding AG
SIX:ROG
202.7B CHF
32%
CH
Novartis AG
SIX:NOVN
183.3B CHF
31%
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP
21%
IE
Endo International PLC
LSE:0Y5F
146B USD
11%
Country FR
Market Cap 116.6B EUR
Operating Margin
23%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Sanofi SA
Glance View

Market Cap
116.6B EUR
Industry
Pharmaceuticals

Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the evolving healthcare demands of a global population. For investors, Sanofi represents a compelling opportunity due to its strong commitment to research and development, which accounted for approximately 16% of its revenue last year. The company’s strategic initiatives focus on enhancing its product line while also forming strategic alliances and partnerships to foster innovation. Furthermore, Sanofi’s solid financial performance, characterized by consistent revenue growth and healthy dividend payouts, showcases its operational efficiency and reliability. As the healthcare landscape continues to shift, Sanofi's agility in adapting to new challenges, coupled with its focus on science and patient needs, sets it apart as a strong contender in the biopharmaceutical industry, providing investors with a platform for sustainable long-term growth.

SAN Intrinsic Value
109.65 EUR
Undervaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
22.8%
=
Operating Profit
14B
/
Revenue
61.6B
What is the Operating Margin of Sanofi SA?

Based on Sanofi SA's most recent financial statements, the company has Operating Margin of 22.8%.